atazanavir + nucleoside reverse transcriptase inhibitors

**Atazanavir + nucleoside reverse transcriptase inhibitors** is a combination antiretroviral regimen used in the treatment of HIV-1 infection. Atazanavir is an HIV-1 protease inhibitor that prevents viral replication by inhibiting the cleavage of Gag and Gag-Pol polyproteins, thereby halting the formation of mature infectious virions[1][2]. Nucleoside reverse transcriptase inhibitors (NRTIs) inhibit the HIV reverse transcriptase enzyme by incorporating themselves into the viral DNA and causing chain termination, which blocks further viral DNA synthesis[4][6]. This combination targets the HIV life cycle at two critical points: reverse transcription and viral maturation, and is commonly used as part of first-line or maintenance highly active antiretroviral therapy (HAART)[1][3][5]. Atazanavir is taken orally, often boosted with ritonavir or cobicistat, and is typically combined with two NRTIs such as tenofovir and emtricitabine or lamivudine for optimal efficacy[1][3][5].

Brand names

Reyataz